Belite Bio (BLTE) Receivables - Other (2022 - 2025)

Belite Bio's quarterly Receivables - Other came in at $700000.0 in Q4 2025, up 21.74% year-on-year from $575000.0 in Q4 2024, and up 21.74% quarter-over-quarter from $575000.0 in Q4 2024.

Belite Bio has reported Receivables - Other for 4 years, with the latest figure at $700000.0 in Q4 2025.

  • For the quarter ending Q4 2025, Receivables - Other rose 21.74% year-over-year to $700000.0; the trailing twelve-month figure through Dec 2025 stood at $700000.0 (up 21.74% YoY), and the FY2025 full-year result was $700000.0, up 21.74% from the prior year.
  • Receivables - Other for Q4 2025 stood at $700000.0, up from $575000.0 in the prior quarter.
  • The five-year high for Receivables - Other was $700000.0 in Q4 2025, with the low at $2000.0 in Q4 2022.
  • Average Receivables - Other over 4 years is $323750.0, with a median of $296500.0 recorded in 2023.
  • Year-over-year, Receivables - Other surged 3094.44% in 2024 and grew 21.74% in 2025.
  • Tracing BLTE's Receivables - Other over 4 years: stood at $2000.0 in 2022, then jumped by 800.0% to $18000.0 in 2023, then surged by 3094.44% to $575000.0 in 2024, then climbed by 21.74% to $700000.0 in 2025.
  • The last three Receivables - Other figures came in at $700000.0 (Q4 2025), $575000.0 (Q4 2024), and $18000.0 (Q4 2023), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn
7 Evaxion A 62.56 Bn 62.54 Bn -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn
10 Belite Bio 4.92 Bn 4.45 Bn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 700,000.00
Dec 31, 2025 700,000.00
Sep 30, 2025 -6,000.00
Sep 30, 2025 -6,000.00
Dec 31, 2024 575,000.00
Dec 31, 2024 575,000.00
Sep 30, 2024 56,000.00
Sep 30, 2024 56,000.00
Dec 31, 2023 818,000.00
Dec 31, 2023 818,000.00
Dec 31, 2022 2,000.00
Dec 31, 2022 2,000.00